Through enhanced diagnostic, disease prevention and tailored treatments, personalized healthcare holds great promise for each of us. Research in this field was long hindered by technical, interoperability, ethical and legal challenges, which prevented access to a wealth of consented biomedical data from patients. SIB has played a key role in coordinating efforts on the national level, and establishing the Swiss infrastructure which is now boosting research in this field, in which over 20 of our groups are active. We are also part of several European public-private partnerships, several of which aiming to facilitate precision medicine in cancer or diabetes. Through outreach activities, we also inform the public about the promise and challenges of precision medicine and the role of bioinformatics to enable it.
Making sense of health data to guide treatment decisions
Impact milestone for the SIB Resource SwissDrugDesign with 10'000 citations
To evaluate the impact of life science databases and software, usage figures...
Genomic deletions and duplications shape rare as well as common disease risk
An understudied type of genetic variants typically associated with rare and...
Lunaphore and SIB secure Innosuisse funding for AI-based assay development tools
The spatial biology company Lunaphore, a Bio-Techne brand, and SIB have been...
Personalizing strategies to better tackle cardiovascular diseases
To better understand cardiovascular disease and optimize future prevention and...
The Swiss Personalized Health Network (SPHN) – Factsheet 2023
In this 2023 factsheet, discover key contributions of the Swiss Personalized...
Unveiling our strategic objectives for a better future
On our 25th anniversary, our institute is publishing an inspiring and...
A new identity to celebrate SIB’s 25 years and the future of life science data
In 25 years, SIB has grown from a handful of visionary scientists to a...